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ABSTRACT 1 
The present study was aimed to investigate the effect of salient microneedle (MN) geometry 2 
parameters like length, density, shape and type on transdermal permeation of Rizatriptan 3 
(RIZ). Studies were carried out using two types of MN devices viz. AdminPatch® arrays 4 
(ADM) (0.6, 0.9, 1.2 and 1.5mm lengths), and laboratory fabricated polymeric MNs (PM) of 5 
0.6mm length.  In the case of the PMs, arrays were applied three times at different places 6 
within a 1.77cm2 skin area (PM-3) to maintain the MN density closer to 0.6mm ADM. 7 
Histological studies revealed that PM, owing to their geometry/design, formed wider and 8 
deeper microconduits when compared to ADM of similar length. Approximately 4.9 and 4.2 9 
fold increase in the RIZ steady state flux values were observed with 1.5mm ADM and PM-3 10 
applications when compared to the passive studies. A good correlation between different 11 
dimensionless parameters like the amount of RIZ permeated (Ct/Cs), thickness (h/L) and 12 
surface area (Sa/L2) of the skin was observed with scaling analyses. Numerical simulations 13 
provided further information regarding the distribution of RIZ in MN treated skin after 14 
application of different MNs.  Overall, the study suggests that MN application enhances the 15 
RIZ transdermal permeation and the geometrical parameters of MNs plays an important role 16 
in the degree enhancement. 17 
 18 
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INTRODUCTION 22 
Transdermal drug delivery (TDD) offers many advantages over conventional oral or injection 23 
delivery methods, for example, avoidance of hepatic first pass metabolism, non-invasive 24 
nature of drug application and ability to deliver the drugs over a prolonged period of time, 25 
etc. All of these factors contribute to improved patient compliance and acceptability of drug 26 
therapy.  TDD is gaining a lot of interest as a possible alternative route of administration for a 27 
wide array of therapeutic agents (1-3). 28 
However, the greatest bottleneck with transdermal delivery is that only a limited number of 29 
drug molecules with a precise combination of physicochemical properties can permeate 30 
through skin at clinically relevant/effective levels. The protective function of the skin, 31 
especially the outermost layer comprising of dead skin cells, the stratum corneum (SC), 32 
which is only 10 to 50 µm thick, imposes limitations on the drug molecules to permeate 33 
across skin and to reach the systemic circulation. However, with the advent of research in 34 
TDD, several techniques have been proposed to attenuate or bypass the barrier function of 35 
skin enabling the efficient delivery of drugs (3-6). 36 
Migraine is a chronic, debilitating headache prevalent in about 19% of the global population 37 
with 2-3 times more incidence in women than in men (7). Rizatriptan, commonly available as 38 
its benzoate salt, (RIZ), an anti-migraine agent, is available as oral IR (immediate release) 39 
and ODT (oral disintegrating tablet) formulations, with an absolute bioavailability of about 40 
45%. Moreover, with these formulations, a good chance of therapeutic failure within 2h after 41 
administering the first dose and recurrence of the attack within 24h were reported (8, 9). 42 
Transdermal delivery may be seen as a good non-invasive alternative for RIZ administration 43 
with prolonged duration of action, increased bioavailability, reduced recurrence and increased 44 
patient compliance. However, RIZ is a relatively hydrophilic molecule and does not have 45 
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ideal properties to permeate through the skin. Hence, a suitable permeation enhancement 46 
technique should be employed to achieve clinically significant rates of drug permeation. 47 
Microneedles (MN), a novel transdermal permeation enhancement technique, are minimally 48 
invasive and potentially painless method of overcoming the barrier properties of skin for 49 
enhanced delivery of drugs (6).  This technique has many advantages when compared to 50 
hypodermic injection, is believed to make conduits of micrometer dimensions in skin layers 51 
in the epidermal layers (especially, SC) and thus believed to enhance the transdermal 52 
permeation of drugs (10). MNs are known to improve the permeation of drug molecules, 53 
including macromolecules like insulin, growth hormone, etc (5, 11-13). It has been reported 54 
in the literature that several geometric parameters of MNs like shape, dimensions, density of 55 
MN on the device and type etc. play important roles in enhancing the transdermal permeation 56 
of drugs (14). There is also interplay of the effect of these variables and, as such, their effects 57 
on the permeation of a drug molecule are generally non-intuitive. As a result, their effects are 58 
best studied for specific case. 59 
Motivated by this idea, the present study was designed as a systematic approach to explore 60 
the effect of MN geometry on the extent of RIZ transdermal permeation enhancement. Two 61 
types of MN devices viz. commercially available AdminPatch® arrays (ADM) (0.6, 0.9, 1.2 62 
and 1.5 mm length) and laboratory fabricated polymeric MN arrays (PM) (0.6 mm length) of 63 
different MN densities were employed in this investigation (Fig 1).  A number of different 64 
techniques like etching, lithography and moulding were discussed widely in the literature for 65 
the manufacture of MNs of different dimensions (100-1800 μm in length), shapes with 66 
different materials (plastics, silicon, ceramics, metals, etc.). Injection moulding offers several 67 
advantages in terms of ease of scalability for bulk manufacture, range of materials and good 68 
reproducibility (15).  In this study, micro-injection moulding was employed for fabrication of 69 
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the polymeric MN arrays (PM) using PEEK LT-3 (polyether ether ketone) as reported in 70 
previous paper (16). 71 
Surface visualization and histological evaluation of skin samples were carried out to confirm 72 
and to study formation miroconduits by application of either types of MN devices.  73 
Moreover, the obtained RIZ permeation data was subjected to mathematical treatment using 74 
scaling analyses to obtain correlations between dimensionless parameters like amount of RIZ 75 
permeated (Ct/Cs) and various variables of the study like surface area (Sa/L2) and thickness 76 
(h/L) of skin based on the principles of Buckingham π theorem as described in a previous 77 
papers (17, 18). Furthermore, numerical simulations using passive diffusion coefficient 78 
values, based on histological section images, were carried out using MATLAB and 79 
COMSOL programmes in order to gain insights into the phenomenon of RIZ transport 80 
behaviour and distribution in the skin layers (18, 19). 81 
 82 
MATERIALS AND METHODS 83 
Materials 84 
AdminPatch® MN arrays were purchased from AdminMed, Sunnyvale, U.S.A.  Rizatriptan 85 
benzoate was obtained from Mylan Laboratories Limited, Hyderabad, India; Sodium 86 
chloride, isopropyl alcohol, propylene glycol and 1%w/v Safranin solution from Loba 87 
Chemie, Mumbai, India; Formic acid, acetonitrile, methanol and HPLC water from Merck 88 
Specialities Pvt. Ltd, Mumbai, India; Haematoxylin and Eosin stain from Sigma-Aldrich, 89 
Bengaluru, India. All the reagents and chemicals used in the study were of HPLC grade.  Pig 90 
ear skin was obtained from local abattoirs. 91 
Fabrication of Polymeric MN (PM) 92 
Moulding of the MNs was performed on a micro-power 15 micro-injection moulding 93 
machine as shown in Fig 2 A. It is the latest micromoulding machine from Battenfeld  94 
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(Wellingborough, UK) and was employed for the fabrication of PM for its high repeatability, 95 
accurate dosing, clean room facility, etc., which is ideal for bulk manufacture of MNs.  PEEK 96 
LT-3 (Polyetheretherketone) is an FDA approved semi-crystalline biomaterial manufactured 97 
by Invibio Inc, Lancashire, UK and is widely employed for medical use. The main feature of 98 
PEEK LT-3 include its excellent processability, dimensional stability and high mechanical 99 
performance and resilient to repeated gamma radiation and was hence selected for the 100 
fabrication of MN arrays (16). The MN mould insert (Fig 2 B) was made out of Stavax ESR 101 
(Bohler-Uddeholm Corp, Elgin, USA). Sink electrical discharge machining (EDM) was used 102 
to create negative MN features into the insert and was outsourced to Isometric tool and 103 
design Inc. (New Richmond, USA). The moulding parameters for PM were mentioned in the 104 
Table I. 105 
MN dimensional evaluation 106 
Scanning electron microscope (SEM): 107 
A Hitachi TM-3000 table-top Scanning Electron Microscope was used for analysis of the MN 108 
insert and needle geometry. The Hitachi TM-300 has a magnification from 15X to 30000X, 109 
sample chamber of 700 mm diameter and 50 mm thickness. It features 5 kV, 15 kV and 110 
analysis observation modes. Because of the high aspect ratio and low contrast of the MNs, 111 
analysis mode was used for imaging. The major advantage of using TM 3000 SEM was it 112 
works under low vacuum and does not need specimen coating. 113 
Confocal laser microscope: 114 
It is very important to measure the tip radius and height of the MNs and the most common 115 
methods used are optical or electron microscopy. Because of its steep and complex structures, 116 
a 3D image analysis gives a better measurement of the needle geometry and quality control. 117 
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In this study an Olympus vertical scanning laser confocal microscope LEXT OLS 4000 was 118 
used to accurately measure the tip radius and height of MN arrays. 119 
The device offers a broad magnification range from 108X to 17280X and the exact 3D 120 
reconstruction of the MNs. The confocal laser microscope LEXT scans the surfaces with a 121 
laser beam with the wavelength of 405 nm thus allowing submicron visualization of material 122 
and component surfaces with the resolution of down to 0.10 µm. Measurements were taken 123 
with the 20X lens using the wide range stitching feature with 20 percent overlap to produce a 124 
measurement area of 5mm x 5mm. A five level brightness switch (Table II) was enabled to 125 
accurately illuminate the specimen. 126 
Analysis of samples 127 
RP-HPLC-PDA method was developed specifically for the analysis of RIZ in the transdermal 128 
permeation samples.  A Shimadzu Prominence HPLC system provided with DGU-20A3 129 
degasser, LC-20AD binary pumps, SIL-20AHT auto sampler and SPD-M20A PDA detector 130 
was used for analysis of the samples.  Data acquisition was carried out using LC solutions 131 
software.  Separation was achieved on an Agilent Eclipse column (150 × 4.6 mm; 5 µm).  132 
The mobile phase comprised of 0.02% v/v formic acid:methanol 75:25 (v/v) at a flow rate of 133 
1 mL/min with an injection volume of 20 µL and the eluents were monitored at 221 nm.  The 134 
developed method was validated as per ICH guidelines. 135 
 136 
Solubility studies  137 
The solubility of RIZ was studied in different vehicle combinations of propylene glycol (PG), 138 
polyethylene glycol-400 (PEG), and saline (S) at 70:30, 80:20 and 90:10% v/v ratios.  To 139 
each vehicle system, excess amount of RIZ was added and vortexed for 1 min in order to 140 
obtain a saturated solution and the solutions were equilibrated at 37°C in an orbital shaker for 141 
24 h.  After equilibration, the samples were centrifuged at 3000 rpm for 10 min and filtered 142 
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through a nylon syringe filter (0.45µm) and all the samples were appropriately diluted and 143 
analysed by HPLC method. 144 
 145 
Skin Preparation 146 
Pig ears were collected from the local abattoirs immediately after animals were killed by 147 
electric current.  The ears were transported to the laboratory in a cooling box without 148 
previous treatment.  In the laboratory, the pig ears were washed carefully with distilled water 149 
and the hair was removed from the external part of pig ear using an electrical hair clipper.  150 
Carefully the full-thickness skin from the external part of the pig ear was separated from 151 
underlying cartilage using a scalpel and excess fat underlying the skin was removed to a 152 
thickness of 1.2mm was employed for the in vitro transdermal permeation studies.  Dermis 153 
side was wiped with isopropyl alcohol to remove the residual adhering fat.  Processed skin 154 
samples were individually wrapped in plastic bags without air entrapment and stored in a 155 
deep freezer at -20°C till further use. 156 
  157 
Application of MNs on skin samples 158 
Prior to the in vitro skin permeation experiments, the skin samples were allowed to brought to 159 
the room temperature and then skin surface was carefully washed with saline.  Two types of 160 
MN devices viz, ADM (0.6, 0.9, 1.2 and 1.5 mm) and PM (0.6mm) were tried to poke the 161 
skin surface under thumb pressure.   In the case of PM, both single (PM-1) and triple (PM-3) 162 
insertions at different places within a 1.77cm2 skin area (PM-3) were made in order to 163 
maintain the MN density closer to ADM of 0.6mm length as shown in Fig 1.  The MNs were 164 
periodically checked in between usage for potential damages of the needles under a 165 
stereomicroscope. 166 
 167 
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Surface visualization and histological examination of the skin samples  168 
To visually confirm the ability of disruption of skin layers by MNs, the arrays were pressed 169 
over the pig ear skin under thumb pressure and held for 1 min.  Then the skin was stained 170 
with safranin dye (1% w/v in water) and wiped with isopropanol cotton swabs for the 171 
identification of the microconduits formed.  In the case of the histological studies the skin 172 
section samples with and without MN treatments were prepared after staining with 173 
haematoxylin and eosin for visualization of skin layers and to display a clear indentation by 174 
MN penetration.  The sections were observed under a microscope (Olympus; Noida, India).  175 
The width and depth of microconduits formed were also calculated in triplicate (n = 3 skin 176 
samples for each MN) with the help of Toup View 3.2 Software (Irwin, U.S.A).  For control, 177 
skin samples without MN treatment were also prepared. 178 
 179 
In Vitro Skin Permeation Studies 180 
The in vitro transdermal permeation studies were performed using a vertical type Franz 181 
diffusion cell apparatus fitted with a water circulation system, a water heater and an eight 182 
stage magnetic stirrer (Orchid Scientifics, Nasik, India). Franz diffusion cells with an 183 
effective diffusion area of 1.77 cm2 and a receptor volume of around 14 mL were used.  184 
Saline was used as the receptor fluid.  Pig ear skin was mounted between the donor and 185 
receptor cells with SC facing towards the donor cell.  The receptor medium was stirred for 186 
uniform drug distribution at a speed of 600 rpm throughout the experiment.  Care was taken 187 
to prevent the air bubbles entrapment underside of the skin (dermis) and receptor solution.  188 
The surface of the skin was maintained at 32°C using a circulating water bath. After 189 
equilibration, 500 µL of donor solutions containing excess amount of RIZ were applied on to 190 
the skin.  Samples (500 µL) were withdrawn from the receptor fluid at six hour increments up 191 
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to 48 hr and replaced with the fresh saline to maintain a constant volume.  All the samples 192 
were stored at 4°C, until analyzed by HPLC. 193 
The cumulative permeation profiles were plotted for cumulative amount of drug permeated 194 
(nmoL/cm2) as a function of time, for untreated and microneedle treated skin.  The flux 195 
values and the respective lag times were obtained from the slope and the X-intercept of the 196 
steady state portion of the cumulative permeation profiles.  Apparent permeability and 197 
diffusion coefficient values were computed from Fick’s first law of diffusion: 198 
 199 
Js is the steady-state flux (nmoL/cm²/hr), M is the cumulative amount of drug permeating the 200 
skin (nmoL/cm²), A is the area of the skin (1.77 cm2), Kp is the apparent permeability 201 
coefficient (cm/hr), and ΔC is the difference in concentrations of RIZ in the donor and 202 
receiver. Sink conditions were maintained in the receiver throughout the experiment and 203 
hence ΔC was approximated to the drug concentration in the donor compartment.  204 
 205 
Enhancement ratios were also computed to evaluate the relative efficiency of different MNs 206 
on the RIZ skin permeation enhancement. The enhancement ratios were calculated as 207 
follows: 208 
𝐸𝐸𝐸𝐸ℎ𝑎𝑎𝐸𝐸𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝐸𝐸𝑎𝑎 𝑅𝑅𝑎𝑎𝑎𝑎𝑅𝑅𝑅𝑅 =  Cumulative amount or Flux obtained after MN applicationCumulative amount or Flux obtained from passive studies 
                     209 
 210 
RIZ content in skin 211 
After the completion of the permeation studies, skin samples were studied for drug 212 
disposition.  The skin tissue exposed to the donor solution was cut with a scalpel and washed 213 
CKJ
dt
dM
A ps
∆==


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
1
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with filtered water and blotted with a paper towel in order to remove the adhered drug to the 214 
surface.  Then skin was minced with a scalpel, and placed in a pre-weighed vial.   The drug 215 
was extracted from the skin by equilibrating with 5 mL of acetonitrile at 32°C in an orbital 216 
shaker.  The solutions were then analyzed by HPLC to determine the RIZ content. 217 
 218 
  219 
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Scaling analyses 220 
Dimensionless correlations between the amount of RIZ permeated (Ct/Cs) and other variables 221 
like thickness (h/L) and surface area (Sa/L2) of skin were made in order to gain insights into 222 
the overall phenomenon of RIZ transdermal permeation enhancement by MN application.  223 
The scaling analyses were carried out based on the principles of Buckingham π theorem 224 
where it is defined that the dimensionless concentration of a drug, which permeates through 225 
skin, can be defined in terms of key non-dimensional parameters (e.g., MN lengths) using the 226 
procedures described in previous papers (17, 18).   227 
Eq.1 describes the relationship of all the model parameters used for such analyses (Table III). 228 
𝐶𝐶𝑡𝑡
𝐶𝐶𝑠𝑠
= 𝐾𝐾 �𝑆𝑆𝑎𝑎𝐿𝐿4𝐾𝐾𝑒𝑒
𝑉𝑉𝑑𝑑ℎ𝐷𝐷
�
𝑛𝑛
   (1) 229 
Where, ‘K’ is a dimensionless constant and ‘n’ is an unknown power; Ct and Cs are the 230 
amount of drug permeated at a given time t (48 h) and the amount of drug loaded in the donor 231 
compartment for diffusion (surface concentration on skin); Sa is the surface area of skin 232 
available for diffusion; L is the length of microneedles; Ke and Vd are the first order 233 
elimination constant and the volume of receptor fluid; ‘h’ is the thickness of skin and D is the 234 
diffusion coefficient of RIZ in skin. 235 
Using Eq.1, the correlations between the dimensionless RIZ concentration (Ct/Cs) against 236 
different dimensionless parameters of study, h/L and Sa/L2, have been established considering 237 
that all other variables remain unchanged. 238 
 239 
Numerical simulations of experimental studies 240 
A set of well-defined numerical simulations were carried out in order to gain insights into the 241 
specific effects of MN shape, dimensions, force of insertion of MN, etc. on the overall 242 
permeation enhancement of RIZ, and also to obtain the information about RIZ distribution 243 
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within the skin layers during permeation, which are otherwise difficult to obtain directly from 244 
the experimental data.  The simulations were carried out using MATLAB (Math Works, MA, 245 
USA) and COMSOL Multiphysics (COMSOL Multiphysics Pvt. Ltd., Stockholm, Sweden) 246 
programmes. The MATLAB programme was use to process the histological sections images 247 
of skin treated with MNs and these processed images were further coupled with the 248 
experimental permeation parameter, e.g., passive diffusion coefficient  and imported into 249 
COMSOL simulator software (18, 19). 250 
 251 
Statistical analysis of the data 252 
Results of the experimental data were subjected to statistical analysis by one way ANOVA 253 
(using Fischer’s LSD post hoc test) using SYSTAT 13 software (Systat Software Inc., San 254 
Jose, USA).  Results with p value of less than 0.05 were considered to have statistically 255 
significant variance.  Mean of replicate measurements (n = 3) with corresponding standard 256 
deviation (SD) was used to represent the data and to plot the graphs. 257 
 258 
RESULTS 259 
Fabrication and characterization of PM 260 
Polymeric MN arrays (PM) were fabricated using (PEEK)-LT3 (polyether ether ketone) 261 
using micro-injection moulding technique, with 25 MN on each array (MN density) and the 262 
array base thickness of 300 µm.  The dimensions of PM, determined using a 3D confocal 263 
imaging (Fig 3 A) and scanning electron microscopy (SEM) (Fig 3 B), were found to be 556 264 
± 30 µm in height with a tip radius of 32 ± 8 µm, with a base thickness of 300 µm and MN 265 
interspacing of approximately 1 mm at the base. 266 
For better comparison and understanding of the difference in the shape/design between PM 267 
and ADM devices, 3D confocal images of 0.6 mm ADM were given in Fig 3 C.  Also the 268 
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difference in base thickness among the devices can be clearly observed from the Fig 1. The 269 
various geometry parameters of both types of MN devices were given in Table IV. 270 
 271 
Analytical Method 272 
A rapid and sensitive HPLC-PDA method was developed for the selective quantification of 273 
RIZ in transdermal permeation studies.  Under the developed LC conditions, RIZ eluted at 274 
2.5 min (Fig 4A) with good peak shape.  Also, the specificity of the method to RIZ was 275 
demonstrated by the UV spectrum and the peak purity index curves (Fig 4B, C).  The method 276 
was validated as per ICH guidelines and complied with all the requirements (Table V) 277 
 278 
Solubility Studies 279 
Solubility studies for RIZ were performed with a view to select appropriate donor vehicle for 280 
conducting in vitro skin permeation studies.  PG:S and PEG:S combinations at 70:30, 80:20 281 
and 90:10 %v/v were studied for RIZ solubility.  The solubility data obtained was shown in 282 
Fig 5.   283 
 284 
Surface visualization and histological examination of skin samples 285 
In order to visually confirm the ability of disruption of skin layers by MNs, the arrays were 286 
pressed over the pig ear skin under thumb pressure and held for 1 min and the skin samples 287 
were stained with safranin (1%w/v).  The digital photographs of MN treated skin were shown 288 
in Fig 6. Histological section images of skin treated with MNs were shown in Fig 7.  From 289 
the images, the stratum corneum disruption and the formation of microconduits across skin 290 
layers was clearly evident.  The average penetration depth (vertical)  (n = 3) of the MNs was 291 
found to be 180.26 ± 30.39, 302.22 ± 22.28, 400.85 ± 20.83, 478.48 ± 67.72 and 338.20 ± 292 
22.66 µm for ADM (0.6, 0.9, 1.2, 1.5 mm) and PM, respectively. 293 
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In vitro permeation studies  294 
The comparative in vitro pig ear skin permeation profiles of RIZ without and with MN 295 
application were shown in Fig 8.  Various RIZ permeation parameters viz. cumulative amount 296 
permeated at the end of 48h, steady state flux, lag time, permeability and diffusion 297 
coefficients without and with microneedle treatment were given in Table VI.   298 
 299 
Scaling analyses 300 
Using scaling analyses, correlations were developed between the dimensionless parameters, 301 
namely, the amount of RIZ permeated (Ct/Cs) and skin thickness (h/L) and surface area of 302 
skin (Sa/L2) in order to derive a better understanding on the effect of specific geometry 303 
parameters of MN, like length (L), on overall permeation enhancement by MNs of same 304 
design (ADM) (Fig 9A, B respectively) (17, 18).  Eqs. 2 and 3 describe such relationships 305 
among the considered parameters within the given range.  These correlations were 306 
determined for given thickness and surface area of skin while the MN length varies (0.6, 0.9, 307 
1.2 and 1.5 mm). 308 
 309 
𝐶𝐶𝑡𝑡
𝐶𝐶𝑠𝑠
= 4.864𝑥𝑥10−3 �ℎ
𝐿𝐿
�
−1.592
 for 0.8 ≤ ℎ
𝐿𝐿
 ≤ 2  ---- (2) 310 
𝐶𝐶𝑡𝑡
𝐶𝐶𝑠𝑠
= 0.224 �𝑆𝑆𝑎𝑎
𝐿𝐿2
�  
−0.796
 for 78.5 ≤ 𝑆𝑆𝑎𝑎
𝐿𝐿2
 ≤ 491.5 ---- (3) 311 
 312 
Good correlation was observed (R2>0.85) between the dimensionless parameters of the study 313 
(Fig 9). 314 
 315 
Numerical simulations of experimental studies 316 
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The numerical simulations were carried out using the procedures discussed in previous papers 317 
based on in vitro passive diffusion coefficient values, coupled with histological section 318 
images (of corresponding MNs) (18, 19). Different stages in processing the histological 319 
section images by MATLAB and COMSOL programmes for simulations were shown in Fig 320 
10. The numerical simulations were able to provide information regarding the skin 321 
distribution of RIZ after applying the MNs at any time point and depth (Fig 10 D). 322 
 323 
DISCUSSION 324 
The shape (conical) and dimensions of the PM were found to be consistent and repeatable 325 
with good tip shape, confirming the complete filling of the PEEK into the MN insert cavity 326 
under the maintained processing conditions (Table I) and the technique used is reliable for the 327 
bulk manufacture of PMs. Moreover, compression tests of PM on a steel plate using Bose 328 
Electroforce 3100 instrument with a 225 N load cell and Wintest® software (Bose, MN, 329 
USA) revealed that the PMs were able to withstand compression forces of up to 8 N.  Plastic 330 
deformation of the PMs was observed at forces greater than 16N, with no tip breaking. (16). 331 
 332 
A rapid and sensitive HPLC-PDA method was developed for the selective quantification of 333 
RIZ in transdermal permeation studies (Fig 4). The method complied with all the 334 
requirements of ICH guidelines (Table V) and was successfully employed for the quantitative 335 
estimation of RIZ in various samples throughout the study. The solubility of RIZ was in the 336 
order 70:30>80:20>90:10 %v/v in both PG:S and PEG:S solvent systems.  Overall, the 337 
solubility of RIZ was significantly higher in PG:S 70:30 %v/v combination when compared 338 
to others (p<0.05) (Fig 5).  Hence, PG:S 70:30 %v/v combination was further selected as the 339 
donor vehicle in permeation studies. 340 
 341 
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Surface visualization of the MN treated skin samples showed clear distinctions in the number 342 
of the microconduits formed as per the length and density of MNs in ADM and PM devices 343 
(Fig 6). Histological section images clearly showed skin layer disruption and the formation of 344 
microconduits (Fig 7).  The average penetration depth (vertical) was about 25-35% for ADM 345 
and 55-60% for the PM MN lengths (Fig 7). Even though the length of the MNs differ in 346 
ADM, the percentage of MN penetration is almost same, which is an indication of uniformity 347 
in thumb pressure under which MNs were applied at different times. 348 
With the ADM devices, as the length of the MNs increased the penetration depth also 349 
increased. However, the microconduits were found to be wider and deeper with PM when 350 
compared to ADM of similar lengths i.e. 0.6 mm. These differences in the efficiency of 351 
creating microconduits in skin layers between the two types of MN devices (ADM and PM) 352 
may be attributed to the differences in geometry parameters like shape, design and type of 353 
fabricating material. Regarding the shape/design, PM being conical (3D) in shape, the 354 
microconduits formed by PM were wider, while that with ADM looks merely like a cut on 355 
the skin (2D) as the arrays of ADM are low in thickness (2D) (Fig 3).  Furthermore, owing to 356 
the sturdy and thick base (when compared to ADM) that supports the solid PM (Fig 1), the 357 
effective resistance (because of the viscoelastic nature) of the skin during application of 358 
arrays may be less for PM, while the ADM might have experienced greater resistance which 359 
is because of their thin base and array design (20), resulting in a relatively shallow 360 
penetration with similar MN lengths (0.6 and 0.9 mm ADM). 361 
 362 
Significant enhancement in RIZ permeation was observed after MNs application onto the 363 
skin (p<0.05) when compared to passive permeation studies (Fig 8). A 1.76, 1.91, 3.55 and 364 
7.41 fold increase in the cumulative amount (48 h) of RIZ permeated was observed with 0.6, 365 
0.9, 1.2 and 1.5 mm ADM treatments, respectively, when compared to passive permeation 366 
17 
 
amount.  A similar trend was observed with other permeation parameters like permeability 367 
and diffusion coefficient values (Table VI).  Significant reduction in the lag time was 368 
observed after application of 1.5 mm ADM when compared to that with passive and other 369 
ADM lengths (p<0.05).   However, there is no statistically significant difference between 370 
passive and 0.6mm and 0.9 and 1.2mm ADM treatments in terms of lag time (p>0.05).  371 
The RIZ flux values were found to be in the order of 1.5mm > 1.2mm > 0.9mm > 0.6mm > 372 
passive with ADM treatments.  A 4.88 fold increase in RIZ flux was observed with the 1.5 373 
mm when compared to passive studies. However, there is no statistically significant 374 
difference between 0.6 and 0.9 mm treatments (p>0.05). It was observed that the 375 
enhancement of RIZ permeation was only marginal with the application of 0.6 and 0.9 mm 376 
ADM when compared to passive studies (Fig 8). This may be due to the fact that the skin 377 
disruption/penetration caused by 0.6 and 0.9 mm ADM was less as supported by histological 378 
section images (Fig 7).  379 
 Moreover, the RIZ permeation was high with 1.5 mm ADM when compared to 0.6, 0.9 and 380 
1.2mm even though the density of MNs is low, which is may be because of longer needle 381 
lengths which intern resulted in deeper skin penetration. 382 
With the PM application, a 1.62 and 6.35 fold increase in the cumulative amount (48 h) of 383 
RIZ permeated was observed with PM-1 and PM-3 treatments, respectively, when compared 384 
to passive permeation amounts.  The lag times were found to be significantly lower for PM-3 385 
when compared to passive and PM-1 treatments (p<0.05). The RIZ flux values were found to 386 
be in the order of PM-3 > PM-1 > passive treatments. A 4.52 and 1.49 fold increase in RIZ 387 
flux was observed with the PM-3 and PM-1, respectively, when compared to passive studies. 388 
A similar trend was observed with other permeation parameters like permeability and 389 
diffusion coefficient values (Table VI) with both the PM treatments. 390 
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Even though, the skin penetration by PM device (with 0.6mm array) was significantly greater 391 
when compared to 0.6 and 0.9 mm ADM, the overall permeation enhancement in terms of 392 
flux, cumulative amount permeated etc. achieved with PM-1 was found to be closer to those 393 
of 0.6 and 0.9mm ADM (p>0.05).  This may be because the needle density of 0.6 and 0.9 mm 394 
ADM was greater when compared to PM-1 (Table III), which may have compensated the 395 
variation in the extent of skin penetration among these MNs, and thus no significant variation 396 
in overall permeation enhancement was observed among these three MNs (p>0.05).   397 
In case of the PM, a single application of array didn’t cover the 1.77cm2 surface area of the 398 
skin and hence in order to maintain the MN density closer to ADM of 0.6mm length the 399 
arrays were applied three times at different places within a 1.77cm2 skin area (PM-3) as 400 
shown in Fig 1.  As the needle density was increased with PM-3, the RIZ transdermal 401 
permeation increased markedly and was similar to that obtained with 1.5 mm ADM (p>0.05). 402 
Moreover, it is intriguing to note although the needle density PM-3 (75 MNs) was 403 
significantly greater when compared to 1.5 mm ADM (31 MNs) the overall RIZ permeation 404 
enhancement was considerably greater with 1.5 mm ADM with significantly shorter lag times 405 
(p<0.05), which may be because of deeper (vertical) penetration into skin. Even though the 406 
depth of the penetration was significantly lower with PM when compared to 1.5 mm ADM, 407 
the comparable permeation enhancement by PM-3 is may be because of higher needle density 408 
as stated earlier and wider microconduits formed as evidenced by histological section images 409 
(Fig 7) 410 
The enhancement in RIZ permeation was found to be in the order of 1.5mm ADM ≥ PM-3 > 411 
1.2mm ADM > 0.9mm ADM ≥ 0.6mm ADM ≥PM-1 > Passive.  Even though, no correlation 412 
of RIZ skin content was observed with different MN treatments, significantly higher amounts 413 
of RIZ were found to be distributed in skin layers at the end of 48h with MN treated studies 414 
and is an indication of potential RIZ skin deposition.   415 
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Overall, the transdermal permeation enhancement of RIZ by MN application is a complex 416 
phenomenon and the permeation enhancement is dependent on the several aspects of the MN 417 
geometry like the shape/design, length and density etc. 418 
 419 
Dimensionless correlations were developed for ADM MNs (same type but differing in 420 
length) using scaling analyses. Good correlations were observed between the dimensionless 421 
parameters (Ct/Cs vs h/L and Ct/Cs vs Sa/L2) (Fig 9). These correlations can be used to predict 422 
the amount of RIZ permeated (Ct/Cs) with high accuracy for other MN lengths in the range of 423 
0.6-1.5 mm with similar design as ADM. 424 
From the results of numerical simulations, the flux was represented by white arrows in the 425 
figures (Fig 10 D) showing obvious increment at the upper layers of the skin which is caused 426 
by MN penetration.  This increment may be extrapolated to a higher drug accumulation rate 427 
at the blood stream as well as shorter lag time for the diffusion to reach its steady state after 428 
the application of MNs.  Based on the simulation results, the diffusion profile of RIZ showed 429 
significant permeation increment with 1.5 mm ADM and PM when compared to other MNs 430 
in the study.  Furthermore, the advantage of greater penetration by PM can be further 431 
magnified by increasing the MN density, as in the case of PM-3. 432 
These simulations can be of great research value as they may be used to predict the degree of 433 
transdermal permeation enhancement of RIZ with other (new) dimensions and designs of 434 
MNs using the respective histological section images and the passive diffusion coefficient 435 
data. 436 
 437 
CONCLUSION 438 
Two types of MN devices (ADM and PM) were employed in this investigation to derive a 439 
greater understanding on the effects of various geometry parameters specifically on the 440 
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transdermal permeation of RIZ by MN application. It was observed that the application of 441 
MNs significantly enhance the transdermal permeation of RIZ across pig ear skin. Moreover, 442 
the type/shape, density and more importantly, the length of MNs (depth of penetration into 443 
skin) were found to play a crucial role in the overall permeation enhancement of RIZ using 444 
this technique.  It may be inferred that the transdermal delivery of RIZ, at clinically 445 
significant levels and in a painless and non-invasive manner, may by possible using MN 446 
application. This investigation can form the basis for further studies (in vivo) and for 447 
optimization of various MN parameters to achieve successful delivery of RIZ via. MN 448 
assisted transdermal delivery systems. 449 
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TABLES 518 
Table I. Microinjection moulding parameters 519 
Parameter Value 
Melt temperature (°C) 400 
Maximum injection velocity 
(mm/s) 
750 
Clamping force (kN) 50 
Holding pressure (bars) 600 
Mould temperature (°C) 210 
 520 
  521 
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Table II. Brightness switch settings used for the confocal measurements 522 
Position(µm) Brightness 
600 49 
550 47.1 
520 49.1 
20 75.5 
0 48.4 
 523 
 524 
  525 
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Table III. Model parameters for dimensional scaling analyses of the data 526 
Parameter Value 
Duration for medication: tm 48 h 
Surface area of skin exposed: Sa 1.77 cm2 
Thickness of stratum corneum: hsc 0.002 cm 
Total Thickness of membrane (distance 
to blood vessel): h 
0.12 cm 
Effective skin thickness: he Variable 
Diffusion coefficient in viable skin: D Variable 
Volume of Fluid in Receptor 
Compartment (distribution): Vd 
14 mL 
Skin surface/Donor concentration: Cs 
Saturated Solution was charged 
as the donor solution 
Microneedle length: L  0.06, 0.09, 0.12 and 0.15 cm 
 527 
  528 
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Table IV. Different geometry parameters of MNs used in the study  529 
Parameter ADM* PM  0.6 0.9 1.2 1.5 
Length (µm) 600 900 1200 1500 560 ± 30 
Number of MNs (1.77 cm2) 187 85 41 31 25 
Shape Flat (2D) Conical (3D) 
Thickness of each MN (µm) 78 (uniform till tip)** 300 (~30 at tip) 
Thickness of array base (µm) 100-200** 300 
Material 
Medical grade stainless steel 
(SS 316L) 
PEEK LT-3 (polyether 
ether ketone) 
*values are from manufacturer (20) 530 
**the width and thickness of the MN and the base varies with length 531 
  532 
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Table V. RIZ HPLC Validation Data 533 
 534 
Linearity (n=3) 
Range 
Regression equation 
Correlation coefficient 
Regression coefficient 
 
0.2-3 µg/mL 
y =78500x-418.87 
R=0.999 
R2=0.999 
Precision (n=6) 
Average peak area of the standard sample (%RSD) 
76214(0.529) 
Accuracy (n=3) 
% Level of addition 
Mean Percent Recovery (%RSD) 
80 100.31 (0.685) 
100.46 (0.34) 
100.08 (0.980) 
100 
120 
 535 
  536 
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Table VI. Permeation parameters of RIZ without and with MN treatments 537 
Skin 
treatment 
Permeation Parameters 
cumulative amount 
permeated at 48h 
(nmoL/cm²) 
steady state 
flux 
(nmoL/cm2/h) 
Lag Time (h) 
Permeability 
coefficient 
(x10-05) 
(cm/hr) 
Diffusion 
coefficient 
(x10-08)   
(cm2/sec) 
Skin Content 
(µg/g) 
Passive 373.451 ± 77.524 12.648 ± 1.212 19.69 ± 4.73 2.271 ± 0.218 7.570 ± 0.726 794.30 ± 174.43 
0.6 ADM 621.665 ± 46.356 18.664 ± 0.84 14.84 ± 1.96 3.348 ± 0.152 11.161 ± 0.507 1213.78 ± 361.77 
0.9 ADM 715.246 ± 89.447 18.675 ± 2.825 9.98 ± 0.91 3.353 ± 0.507 11.178 ± 1.691 1200.94 ± 260.13 
1.2 ADM 1328.277 ± 111.659 33.435 ± 3.182 9.87 ± 1.38 6.004 ± 0.571 20.012 ± 1.905 1015.54 ± 148.37 
1.5 ADM 2767.532 ± 209.109 61.756 ± 4.260 4.17 ± 0.85 11.089 ± 0.756 36.963 ± 2.550 1566.92 ± 628.71 
PM-1 602.023 ± 17.269 18.858 ± 1.35 16.31 ± 2.05 3.387 ± 0.243 11.29 ± 0.809 1247.31 ± 445.51 
PM-3 2358.39 ± 314.393 57.199 ± 9.03 7.06 ± 1.61 10.273 ± 1.62 34.243 ± 5.406 1338.26 ± 345.97 
 538 
  539 
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Fig 9 567 
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LEGENDS TO FIGURES 572 
Fig 1. Different MNs used in the study 573 
Fig 2. (A) Battenfeld micro-power 15 moulding machine; (B) (a) 3D drawing of the 574 
microneedle insert (b) dimensions of the insert created using Solid-works CAD software 575 
(dimensions are in mm) 576 
Fig 3. (A) 3D confocal image of (a) front view of the PEEK MN array (b) Single MN of 577 
PEEK (c) line measurement of the needle array; (B) SEM image of the PEEK MNs (a) single 578 
needle 250X (b) single needle 1200x (c) single needle 2000x; (C) Representative 3D confocal 579 
image of 0.6 ADM showing its design parameters 580 
Fig 4. RIZ Chromatogram (A); UV Spectrum (B); Peak Purity Index (C) 581 
Fig 5. Solubility Data of RIZ in PG:S and PEG:S Solvent Systems 582 
Fig 6. Surface images of stained skin without and with MN treatment 583 
Fig 7. Typical histological section which were used for MN penetration depth calculation of 584 
ADM and PM in skin (ToupView® screenshot) 585 
Fig 8. Comparative in vitro skin permeation profiles of RIZ from passive and MN treatments 586 
Fig 9. Scaling relationship of different dimensionless groups for permeation of RIZ– (A) 587 
Effects of dimensionless length of microneedles; (B) Effects of dimensionless surface area 588 
for diffusion 589 
Fig 10. A - The histological section images of skin. B, C - Images treated and processed with 590 
MATLAB program. D – Drug distribution using images simulated in COMSOL 591 
